Department of Surgery, Supportive Care in Cancer, University of Rochester, 265 Crittenden Blvd., Rochester, NY 14642, United States; Wilmot Cancer Institute, Rochester, NY 14642, United States.
Department of Psychiatry, University of Michigan, Ann Arbor, MI 48109, United States.
J Neuroimmunol. 2022 Jan 15;362:577769. doi: 10.1016/j.jneuroim.2021.577769. Epub 2021 Nov 19.
Cancer-related cognitive decline (CRCD) is a clinically important problem and negatively affects daily functioning and quality of life. We conducted a pilot longitudinal study from pre- to post-chemotherapy in patients with breast cancer to assess changes in inflammation and cognition over time, as well as the impact of baseline cytokine level on post-chemotherapy cognitive scores. We found that concentrations of IL-6, MCP-1, sTNFRI, and sTNFRII significantly increased in patients, while IL-1β significantly decreased (p < 0.05). After controlling for covariates, increases in IL-6 and MCP-1 were associated with worse executive function and verbal fluency in patients from pre- to post-chemotherapy (p < 0.05). Higher baseline IL-6 was associated with better performance on executive function and verbal fluency post chemotherapy (p < 0.05). Overall, these results suggest that chemotherapy-associated increases in cytokines/receptors is associated with worse cognitive function. Larger studies are needed to confirm these findings.
癌症相关认知衰退（CRCD）是一个临床重要问题，会对日常功能和生活质量产生负面影响。我们对乳腺癌患者进行了一项从化疗前到化疗后的前瞻性纵向研究，以评估炎症和认知随时间的变化，以及基线细胞因子水平对化疗后认知评分的影响。我们发现，白细胞介素 6（IL-6）、单核细胞趋化蛋白 1（MCP-1）、可溶性肿瘤坏死因子受体 1（sTNFRI）和可溶性肿瘤坏死因子受体 2（sTNFRII）的浓度在患者中显著增加，而白细胞介素 1β（IL-1β）显著减少（p<0.05）。在控制协变量后，从化疗前到化疗后，IL-6 和 MCP-1 的增加与患者执行功能和言语流畅性的下降相关（p<0.05）。较高的基线 IL-6 与化疗后执行功能和言语流畅性的表现较好相关（p<0.05）。总体而言，这些结果表明，与化疗相关的细胞因子/受体的增加与认知功能下降有关。需要更大规模的研究来证实这些发现。
